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Background: There is growing evidence that tumors of the inner quadrants (especially the
lower-inner quadrant) metastasize more often to the internal mammary chain (IMC). As these
metastases are not investigated, patients with lower-inner quadrant tumors have an increased
risk of being under-staged and under-treated and may therefore have a higher risk of death
from breast cancer.
Methods: We identiﬁed all 1522 women operated for stage I breast cancer between 1984 and
2002 recorded at the population-based Geneva Cancer Registry. We compared breast cancer
mortality risk by tumor location with multivariate Cox regression analysis that accounted for
all factors linked to tumor location and survival.
Results: Ten-year disease-speciﬁc survival was 93% (95%CI: 91–94%). Patients with breast
cancer of the lower-inner quadrant (n = 118; 7.8%) had an importantly increased risk of
dying of breast cancer compared to women with breast cancer of the upper-outer quadrant
(multiadjusted Hazard Ratio: 2.3, 95%CI: 1.1–4.5, P = 0.0206). The over-mortality associ-
ated with this quadrant was particularly evident for tumors >10 mm (multiadjusted HR: 3.6,
95%CI: 1.6–7.9, P = 0.0016). There was no increased breast cancer mortality risk for tumors
located in other quadrants.
Conclusions: Tumor location in the lower-inner quadrant is an independent and important
prognostic factor of stage I breast cancer. Further research is needed to evaluate if the over-
mortality of patients with stage I cancer of the lower-inner quadrant is indeed a result of
under-treatment due to undetected IMC metastases. If so, patients with stage I breast cancer
of the lower-inner quadrant are good candidates for systematic IMC investigation.
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With the generalization of mammography screen-
ing, many breast cancers are detected at an early
stage. Women diagnosed with tumors of £ 20 mm,
without lymph node involvement and distant metas-
tases (T1 N0 M0, stage I), have a ﬁve-year disease-
speciﬁc survival of approximately 98%.1 Despite this
excellent general prognosis, some patients with early
stage breast cancer die of their disease. These deaths
are often related to poor tumor differentiation,
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absence of hormonal receptors, or suboptimal treat-
ment.2,3 Erroneous staging could also be a reason for
some of these breast cancer deaths.
Veronesi and colleagues performed a systematic
surgical evaluation of the internal mammary chain
(IMC) and found that approximately 10% of breast
cancers without axillary lymph node involvement
metastasize to the IMC.4 This risk of IMC involve-
ment increases with tumor size.4,5 In addition, the
presence of IMC metastases depends on tumor
location in the breast, with a higher prevalence of
IMC metastases in tumors of the inner quadrants,
especially the lower-inner quadrant.6–8
The IMC is not routinely investigated for the
presence of lymph node metastases, and breast cancer
is classiﬁed as lymph node negative on the basis of
axillary lymph node investigations only. Undetected
IMC metastases, therefore, lead to under-staging of
patients without axillary lymph node involvement
and to under-treatment of stage I patients who have
no indication of adjuvant chemotherapy. There is
growing evidence that tumors occurring in the inner
quadrants have a higher breast cancer mortality.9–12
However, the real impact of tumor location on the
risk of IMC node metastases and on prognosis is still
controversial, mainly because of the inconclusive
ﬁndings in older studies.4,13–15
We used data from the Geneva Cancer Registry to
evaluate the impact of tumor location on breast
cancer mortality among women with stage I disease.
PATIENTS AND METHODS
The Geneva Cancer Registry records all incident
cancer cases occurring in the population of the can-
ton since 1970. Registration is based on various
sources of information and can be considered as
accurate, as attested by its low percentage (2%) of
cases recorded from death certiﬁcates only. Every
public hospital, private clinic, pathology laboratory,
and physician is requested to report all cancer cases.
Individual clinical ﬁles from the university public
hospitals are systematically consulted and inquiry
forms are sent to physicians for patients treated in the
private sector. The registry actively assesses survival
by an annual, systematic check of vital status in the
ﬁles of the Cantonal Population Oﬃce and passively
by routine examination of hospital records and death
certiﬁcates. The cause of death is systematically re-
corded and validated. Recorded data include soci-
odemographic characteristics, method of discovery,
tumor characteristics (coded according to the Inter-
national Classiﬁcation of Diseases for Oncology
[ICD-O]), stage (according to tumor, lymph node,
and metastasis classiﬁcation TNM), treatment during
the ﬁrst six months after diagnosis, healthcare sector,
and date and cause of death (coded according to the
World Health Organizations classiﬁcation).
We selected all women operated between 1984 and
2002 (n = 1695) for invasive stage I breast cancer,
deﬁned as pathological pT1 (£ 2 cm), pN0 (no lymph
node invasion), and without distant metastases. We
excluded women with other breast cancers (n = 108)
or other invasive cancers (except non-melanoma skin
cancer) (n = 65) before or within six months after
their breast cancer diagnosis. The study ﬁnally in-
cluded 1522 women.
Variables of interest included age (in continuous),
period of diagnosis (1984–1989; 1990–1994; 1995–
1999; 2000–2002), method of discovery (symptoms or
fortuitous, i.e. diagnosis during the work-up of an
unrelated illness, breast self-examination, and
screening), civil status (single, married, widowed, and
divorced/separated), place of birth (Switzerland,
Southern Europe, and other), socioeconomic status
based on the womans last occupation (high, middle,
low, unknown), and healthcare sector in charge of
breast cancer surgery (private clinics or public uni-
versity hospitals).
Histologic types were regrouped as ductal (ICD-O
codes 8010, 8140, and 8500), lobular (ICD-O codes
8520 and 8522), mucinous (ICD-O codes 8480 and
8481), and other. Tumor diﬀerentiation was classiﬁed
as good (grade I), moderate (grade II), poor (grade
III), or unknown. Estrogen receptor status was clas-
siﬁed as negative, positive (when ‡ 10% of cells ex-
pressed estrogen receptors), or unknown. Tumor size
was regrouped as 1–10 mm, 11–20 mm, or unknown.
IMC lymph node status was not systematically as-
sessed during the study period in Geneva and the
Geneva Cancer Registry has no information on IMC
lymph node involvement. Surgery was classified as
mastectomy, surgery with positive margins, and
breast-conserving surgery. Radiotherapy was con-
sidered as yes vs. no. Systemic treatment was cate-
gorized as chemotherapy (yes, no) and hormone
therapy (yes, no).
We considered the following anatomical breast
locations: upper-outer quadrant (ICD-O codes
C50.4, C50.6), upper-inner quadrant (ICD-O code
C50.2), lower-outer quadrant (ICD-O code C50.5),
lower-inner quadrant (ICD-O code 50.3), nipple and
central portion of the breast (ICD-O codes C50.0,
C50.1), and overlapping quadrant (ICD-O code
C50.8), and unknown (ICD-O code C50.9).
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Associations between tumor location and soci-
odemographic, tumor and treatment characteristics
were evaluated by chi-square test. With multivariate
logistic regression analysis, we identiﬁed factors
independently and signiﬁcantly linked to tumor
location.16 Breast cancer-speciﬁc survival was calcu-
lated using the actuarial method, considering death
from breast cancer only. We applied the log-rank test
to evaluate differences in survival curves. By means of
univariate Cox proportional hazards analysis, we
identiﬁed all variables signiﬁcantly associated with
breast cancer mortality. With multivariate analysis,
adjusting for all variables signiﬁcantly associated
with breast cancer mortality or tumor location, we
estimated the effect of tumor location on breast
cancer mortality.
Because larger tumors are more prone to metas-
tasize, we tested for the interaction between tumor
location and size to investigate if the eﬀect of location
was similar for larger (11–20 mm) and smaller tumors
(1–10 mm).16 Moreover, because chemotherapy de-
creases the higher mortality associated with positive
lymph nodes, we also tested for interaction between
tumor location and use of adjuvant chemotherapy.
Statistical analyses were performed with SPSS soft-
ware (SPSS 11.5 version Inc., Chicago, IL).
RESULTS
Among the 1522 patients operated for stage I
breast cancer, the most common tumor location was
the upper-outer quadrant (39%), followed by lesions
located in overlapping quadrants (27%), the upper-
inner quadrant (14%), the lower-outer quadrant
(8%), the lower-inner quadrant (8%), and the cen-
tral portion of the breast and the nipple (4%). The
median follow-up was 7.7 years and 472 patients
(31%) had a follow-up of 10 years or more. During
the study period, 81 patients (5%) died as a result of
breast cancer and 130 patients (8%) were lost to
follow-up as they had left Geneva for another can-
ton or country. Ten-year speciﬁc survival was 93%
(95%CI: 91–94%).
Breast cancer-speciﬁc survival curves according to
tumor location are presented in Fig. 1. The 10-year
speciﬁc survival was 94% (95%CI: 91–96%) for pa-
tients with cancer of the upper-outer quadrant, 96%
(95%CI: 92–99%) for the upper-inner quadrant, 91%
(95%C: 85–98%) for the lower-outer quadrant,
94% (95%CI: 87–100%) for the central part of the
breast and the nipple, and 93% (95%CI: 89–96%) for
overlapping lesions. For patients with tumors of the
lower-inner quadrant, however, the 10-year disease
specific survival was significantly lower, 88% (95%CI:
81–96%, P log-rank test 0.0002).
Table 1 shows that tumors of the lower-inner
quadrant were less often detected by screening (P =
0.011), were less frequently of lobular histology
(P = 0.014), were more often poorly differentiated
(P = 0.031), had less frequently breast conserving
surgery andmore frequentlymastectomy (P = 0.003),
and received less often hormone therapy (P = 0.031).
In themultiadjusted logistic regression, only histology,
poor differentiation, and type of surgery remained
signiﬁcantly and independently associated with tumor
location in the lower-inner quadrant.
Tables 2 and 3 present the effect of patient and
tumor characteristics and treatments on breast cancer
mortality. In the multivariate model, we included all
variables that were signiﬁcantly associated with
mortality in univariate analysis (i.e. age, period,
method of discovery, grade, tumor size, surgery,
radiotherapy, tumor location), factors signiﬁcantly
associated with tumor location (i.e. method of
discovery, histologic type, grade, type of surgery, and
hormone therapy), period of diagnosis, and age.
Table 4 presents the impact of tumor location on
breast cancer mortality. In multiadjusted Cox pro-
portional hazard analysis, tumor location remains a
signiﬁcant prognostic factor. Women with tumors
located in the lower-inner quadrant of the breast had
a more than two-fold increased risk of dying as a
result of breast cancer compared with women with
tumors of the upper-outer quadrant (multi-adjusted
HR: 2.3, 95%CI: 1.1–4.5, P = 0.021). Tumor loca-
tion in other quadrants was not associated with a
signiﬁcantly altered mortality risk.
The eﬀect of lower-inner location appeared to
be more obvious in patients with tumors larger
than 10 mm (n = 1001, multi-adjusted HR: 3.6,
95%CI: 1.6–7.9, P = 0.002) than among patients with
smaller tumors (n = 491, age adjusted HR: 1.0,
95%CI: 0.2–4.6, P = 0.970) and in patients who did
not receive adjuvant chemotherapy (n = 1,261, multi-
adjusted HR: 2.5, 95%CI: 1.2–5.4, P = 0.016) than in
patients who underwent chemotherapy (n = 261, age-
adjusted HR: 1.6, 95%CI: 0.2–13.2, P = 0.662).
However, none of the interaction tests between loca-
tion and size or between location and chemotherapy
were statistically signiﬁcant (P = 0.134 and
P = 0.913, respectively). Since we observed only few
deaths (n = 20) among patients with tumors £ 10 mm
and among patients with chemotherapy (n = 15), we
adjusted the hazard ratios only for age in these sub-
group analyses.
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DISCUSSION
This study shows that tumor location within the
breast is an important and independent prognostic
factor of early-stage breast cancer. After adjustment
for all factors linked to tumor location or prognosis,
patients with tumors of the lower-inner quadrant
have a more than two-fold increased risk of dying as
a result of breast cancer compared to patients with
tumors of the upper-outer quadrant. No diﬀerence in
mortality from breast cancer was observed for the
other tumor locations. Diﬀerences in tumor charac-
teristics or treatment did not explain the over-mor-
tality associated with the lower-inner quadrant. The
results of this study also suggest that the impact of
tumor location is more pronounced for women with
larger tumors and for women who are not treated
with adjuvant chemotherapy.
We acknowledge that we had information on vari-
ous prognostic factors for breast cancer. However, for
a relatively high proportion of patients (49%), we had
no information on estrogen receptor status as this
information became available only after 1995. When
considering only patients diagnosed after this date
(n = 798, proportion of patients with unknown
receptor status: 3%), we observed similar results
(multiadjusted HR for tumors of the lower-inner
quadrant compared to the upper-outer quadrant: 3.7,
95% CI: 0.7–18.7, P = 0.110). We also acknowledge
that our study has limited power for subgroup analyses
due to the relatively low number of breast cancer
deaths occurring in patients with stage I breast cancer.
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Year  1st 5th 10th  15th  18th  
Center, nipple  54 36 25 10 4 
Upper-outer  588 424 217 74 30 
Upper-inner  212 137 70 27 11 
Overlapping  413 283 137 55 24 
Lower-outer  118 82 43 24 9 
Lower-inner  118 84 45 18 6 
a Survival curves derived from Cox model adjusted for age (variable in continuous), period of 
diagnosis, method of discovery, grade, tumor size, surgery, radiotherapy, tumor location, histologic 
type and hormone therapy; Only deaths from breast cancer are considered. 
FIG. 1. Speciﬁc survival curvesa according to
tumor location among women operated for
stage 1 breast cancer, Geneva Cancer Registry,
1984–2002.
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Today, staging for breast cancer is mainly based on
axillary lymph node status. Systematic IMC investi-
gation stopped at the beginning of the 1980s after the
publication of two important trials reporting no
survival beneﬁt for patients with negative axillary
lymph nodes who underwent IMC dissection.5,17
However, none of these patients received adjuvant
therapy, even if they had axillary or IMC lymph node
metastases. This could explain the lack of efﬁcacy of
IMC staging, as lymph node dissection is only a
staging and not a curative procedure.5
Lymph node status, either axillary or internal
mammary, is an important prognostic factor for
patients with operable disease.17,18 Patients with
IMC metastases have an impaired prognosis com-
pared to patients with no mammary or axillary
lymph node metastases (10-year survival of 53 vs.
80%, respectively) and they have a similar survival as
TABLE 1. Patient and tumor characteristics according to tumor location among patients operated for stage I breast cancer,
Geneva Cancer Registry, 1984–2002
Tumor location
Lower-inner quadrant Other
P value for X2 of
heterogeneity
Total n = 118 (%) N = 1404 (%)
Age group
< 40 8 (6.8) 73 (5.2) 0.673
40–49 21 (17.8) 268 (19.1)
50–59 31 (26.3) 450 (32.1)
60–69 38 (32.2) 373 (26.6)
70–79 17 (14.4) 196 (14.0)
‡ 80 3 (2.5) 44 (3.1)
Period of diagnosis
1984–1989 38 (32.2) 313 (22.3) 0.100
1990–1994 26 (22.0) 347 (24.7)
1995–1999 32 (27.1) 416 (29.6)
2000–2002 22 (18.6) 328 (23.4)
Method of discovery
Symptoms/fortuitous 60 (50.8) 528 (37.6) 0.011
Self-examination 22 (18.6) 274 (19.5)
Screening 36 (30.5) 602 (42.9)
Histologic type
Ductal 99 (83.9) 1174 (83.6) 0.014
Lobular 3 (2.5) 119 (8.5)
Mucinous 3 (2.5) 35 (2.5)
Other 13 (11.0) 76 (5.4)
Grade
I 30 (25.4) 529 (37.7) 0.031
II 47 (39.8) 526 (37.5)
III 21 (17.8) 186 (13.2)
Unknown 20 (16.9) 163 (11.6)
Tumor size
1–10 mm 37 (31.4) 454 (32.3) 0.947
11–20 mm 79 (66.9) 922 (65.7)
Unknown 2 (1.7) 28 (2.0)
Estrogen receptor status
Negative 8 (6.8) 95 (6.8) 0.254
Positive 44 (37.3) 631 (44.9)
Unknown 66 (55.9) 678 (48.3)
Surgery
Mastectomy 38 (32.2) 361 (25.7) 0.003
Positive margins 6 (5.1) 20 (1.4)
Breast-conserving surgery 74 (62.7) 1023 (72.9)
Radiotherapy
Yes 85 (72.0) 1066 (75.9) 0.344
No 33 (28.0) 338 (24.1)
Chemotherapy
Yes 17 (14.4) 244 (17.4) 0.411
No 101 (85.6) 1160 (82.6)
Hormone therapy
Yes 46 (39.0) 692 (49.3) 0.031
No 72 (61.0) 712 (50.7)
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patients with axillary lymph node metastases.15 The
efﬁcacy of adjuvant chemotherapy to reduce mor-
tality in patients with lymph node positive disease
has been well established.19 Adjuvant radiotherapy
of the IMC is still controversial and under investi-
gation.20,21 Misclassiﬁcation of patients as having
lymph node negative disease has minor consequences
if adjuvant chemotherapy is already indicated. For
patients who have no indication for adjuvant che-
motherapy, such under-staging results in under-
treatment and probably in a higher risk of death
from breast cancer.
IMC investigation is a rather invasive procedure,
even with minimally invasive techniques. Are the
available data suﬃcient to propose systematic IMC
investigations for women who have no indication for
adjuvant chemotherapy and present stage I breast
cancer located in the lower-inner quadrant? In fact,
there is growing evidence that the lower-inner quad-
rant drains more often to the IMC than the other
quadrants.8,22,23 In particular, Shahar and colleagues
recently reported that 43% of the tumors of the lower-
inner quadrant drains to the IMC compared to about
30% to the lower-outer quadrant or central portion,
and approximately 15% of the other quadrants.8 Some
authors, though, concluded that the risk of IMC
metastases does not depend on the quadrant. In par-
ticular, the large study on extended radical mastec-
tomy performed by Veronesi and colleagues4 showed
an equal rate of IMC metastases for the inner and
central quadrants (20%) and the outer quadrants
(16%). Unfortunately, the 90 patients with tumors of
the inner-lower were considered jointly with the 634
patients with tumors of the other inner and central
quadrants. A reanalysis of this important series
could therefore be particularly important to conﬁrm
whether IMCmetastases aremore frequent for cancers
of the lower-inner quadrant or not.
TABLE 2. Distribution and effect of sociodemographic characteristics, period of diagnosis and sector of care on breast cancer
mortality among women operated for stage I breast cancer, Geneva Cancer Registry, 1984–2002
Patient characteristics
Breast cancer mortality
N % N of death % 10-year survival (95%CI) Age-adjusted HR (95%CI) Multiadjusted HRa (95%CI)
Age group
< 40 81 5.3 8 9.9 0.82 (0.70–0.94) 2.1b (0.9–4.8) 1.4b (0.6–3.2)
40–49 289 19.0 19 23.5 0.93 (0.89–0.96) 1.2b (0.6–2.2) 0.8b (0.4–1.6)
50–59 481 31.6 21 25.9 0.93 (0.89–0.96) 1 (reference) 1 (reference)
60–69 411 27.0 17 21.0 0.94 (0.90–0.97) 1.0b (0.5–1.8) 0.8b (0.4–1.6)
70–79 213 14.0 14 17.3 0.95 (0.92–0.98) 1.3b (0.7–2.6) 1.2b (0.6–2.5)
‡ 80 47 3.1 2 2.5 0.95 (0.86–1.00) 1.0b (0.2–4.4) 0.6b (0.1–2.9)
Period of diagnosis
1984–1989 351 23.1 44 54.3 0.89 (0.85–0.92) 1 (reference) 1 (reference)
1990–1994 373 24.5 22 27.2 0.95 (0.92–0.97) 0.6 (0.3–1.0) 0.9 (0.5–1.6)
1995–1999 448 29.4 14 17.3 0.95c (0.92–0.98) 0.5 (0.3–1.0) 1.2 (0.5–3.0)
2000–2002 350 23.0 1 1.2 0.99d (0.98–1.00) 0.3 (0.0–1.9) 0.6 (0.1–5.6)
Method of discovery
Symptoms/fortuitous 588 38.6 56 69.1 0.90 (0.88–0.93) 1 (reference) 1 (reference)
Breast self-examination 296 19.4 6 7.4 0.95c (0.90–1.00) 0.5 (0.2–1.2) 0.6 (0.2–1.8)
Screening 638 41.9 19 23.5 0.95 (0.93–0.98) 0.5* (0.3–0.9) 0.8 (0.4–1.3)
Civil status
Single 186 12.2 12 14.8 0.91 (0.85–0.97) 1 (reference) 1 (reference)
Married 916 60.2 51 63.0 0.92 (0.90–0.94) 0.8 (0.4–1.5) 1.0 (0.5–1.9)
Widowed 211 13.9 8 9.9 0.97 (0.94–1.00) 0.6 (0.2–1.4) 0.7 (0.2–1.7)
Divorced, separated 209 13.7 10 12.3 0.92 (0.86–0.97) 0.7 (0.3–1.6) 0.8 (0.3–1.8)
Place of birth
Switzerland 816 53.6 45 55.6 0.93 (0.91–0.95) 1 (reference) 1 (reference)
Southern Europe 386 25.4 21 25.9 0.93 (0.89–0.96) 1.0 (0.6–1.7) 0.9 (0.5–1.6)
Other 320 21.0 15 18.5 0.92 (0.87–0.96) 1.1 (0.6–1.9) 1.1 (0.6–2.0)
Socioeconomic status
High 204 13.4 10 12.3 0.94 (0.90–0.98) 1 (reference) 1 (reference)
Middle 686 45.1 39 48.1 0.92 (0.90–0.95) 1.1 (0.6–2.3) 1.1 (0.5–2.2)
Low 267 17.5 13 16.0 0.93 (0.89–0.97) 1.0 (0.4–2.3) 0.9 (0.4–2.3)
Unknown 365 24.0 19 23.5 0.92 (0.89–0.96) 1.0 (0.4–2.1) 1.0 (0.4–2.2)
Sector of care
Private 917 60.2 45 55.6 0.93 (0.91–0.95) 1 (reference) 1 (reference)
Public 605 39.8 36 44.4 0.92 (0.89–0.95) 1.3 (0.8–2.0) 1.2 (0.8–2.0)
a Hazard ratio adjusted for age (variable in continuous), period of diagnosis, method of discovery, grade, tumor size, surgery, radiotherapy,
tumor location, histologic type, and hormone therapy; b not adjusted for age, * P < 0.05, ** P < 0.01, *** P < 0.001; c 9-year speciﬁc
survival; d 4-year speciﬁc survival.
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Studies on the eﬀect of tumor location on prog-
nosis report inconsistent results. Some studies showed
higher risks of death from breast cancer in patients
with tumors of the inner quadrants,9,10,12 or inner
quadrants plus central portion of the breast,11 or
lower quadrants,24 or all quadrants except the upper-
outer quadrant,25 whereas other studies showed no
association whatsoever between tumor location and
breast cancer prognosis.13–15,26
These inconsistencies could be explained by the
fact that some studies that reported no associa-
tion date from an era when women did not receive
TABLE 3. Distribution and effect of tumor characteristics and treatment on breast cancer mortality among women operated for
stage I breast cancer, Geneva Cancer Registry, 1984–2002
Tumor characteristics
and treatment
Breast cancer mortality
N % N of death % 10-year survival (95%CI) Age-adjusted HR (95%CI) Multiadjusted HRa (95%CI)
Histologic type
Ductal 1273 83.6 71 87.7 0.92 (0.90–0.94) 1 (reference) 1 (reference)
Lobular 122 8.0 3 3.7 0.94 (0.88–1.00) 0.5 (0.2–1.7) 0.6 (0.2–2.0)
Mucinous 38 2.5 2 2.5 0.96 (0.87–1.00) 0.8 (0.2–3.4) 1.0 (0.2–4.5)
Other 89 5.8 5 6.2 0.94 (0.88–1.00) 0.8 (0.3–2.0) 0.7 (0.2–1.8)
Grade
I 559 36.7 12 14.8 0.97 (0.94–0.99) 1 (reference) 1 (reference)
II 573 37.6 31 38.3 0.93 (0.90–0.95) 2.2* (1.1–4.2) 1.9 (1.0–3.8)
III 207 13.6 19 23.5 0.86 (0.80–0.92) 3.9*** (1.9–8.0) 3.5*** (1.7–7.4)
Unknown 183 12.0 19 23.5 0.91 (0.86–0.95) 2.6* (1.2–5.4) 1.6 (0.7–3.7)
Tumor size
1–10 mm 491 32.3 20 24.7 0.94 (0.91–0.97) 0.7 (0.4–1.1) 0.7 (0.4–1.2)
11–20 mm 1001 65.8 54 66.7 0.93 (0.91–0.95) 1 (reference) 1 (reference)
Unknown 30 2.0 7 8.6 0.75 (0.57–0.93) 2.6* (1.2–5.8) 2.8* (1.1–7.1)
Estrogen receptors status
Negative 103 6.8 5 6.2 0.92b (0.86–0.99) 1 (reference) 1 (reference)
Positive 675 44.3 9 11.1 0.96b (0.92–0.99) 0.3 (0.1–1.0) 0.6 (0.2–2.0)
Unknown 744 48.9 67 82.7 0.92 (0.90–0.94) 0.7 (0.3–1.9) 0.8 (0.1–7.8)
Surgery
Mastectomy 399 26.2 37 45.7 0.90 (0.87–0.94) 1 (reference) 1 (reference)
Breast-conserving surgery 1097 72.1 42 51.9 0.94 (0.92–0.96) 0.6* (0.4–0.9) 0.8 (0.4–1.7)
Positive margins 26 1.7 2 2.5 0.94 (0.83–1.00) 3.4 (0.8–14.4) 4.0 (0.8–19.4)
Radiotherapy
Yes 1151 75.6 48 59.3 0.93 (0.91–0.95) 1 (reference) 1 (reference)
No 371 24.4 33 40.7 0.92 (0.88–0.95) 1.6* (1.0–2.5) 1.1 (0.5–2.3)
Chemotherapy
Yes 261 17.1 15 18.5 0.90 (0.84–0.95) 1 (reference) 1 (reference)
No 1261 82.9 66 81.5 0.93 (0.91–0.95) 0.8 (0.4–1.4) 1.0 (0.5–1.8)
Hormone therapy
Yes 738 48.5 16 19.8 0.94 (0.90–0.97) 1 (reference) 1 (reference)
No 784 51.5 65 80.2 0.92 (0.89–0.94) 1.7 (1.0–3.1) 1.4 (0.7–2.8)
aHazard ratio adjusted for age (variable in continuous), period of diagnosis, method of discovery, grade, tumor size, surgery, radiotherapy,
tumor location, histologic type, and hormone therapy; * P < 0.05, ** P < 0.01, *** P < 0.001; b 9-year speciﬁc survival as information on
estrogen receptors was available only from 1995.
TABLE 4. Distribution and effect of tumor location on breast cancer mortality among women operated for stage I breast cancer,
Geneva Cancer Registry, 1984–2002
Patient distribution
Breast cancer mortality
N % N of death % 10-year survival (95%CI) Age-adjusted HR (95%CI) Multiadjusted HRa (95%CI)
Location
Upper-outer quadrant 588 38.6 25 30.9 0.94 (0.91–0.96) 1 (reference) 1 (reference)
Upper-inner quadrant 212 13.9 9 11.1 0.96 (0.92–0.99) 1.0 (0.5–2.2) 1.0 (0.5–2.2)
Lower-outer quadrant 118 7.8 7 8.6 0.91 (0.85–0.98) 1.3 (0.6–3.0) 1.3 (0.6–3.1)
Lower-inner quadrant 118 7.8 13 16.0 0.88 (0.81–0.96) 2.6** (1.3–5.0) 2.3* (1.1–4.5)
Centre, nipple 54 3.5 2 2.5 0.94 (0.87–1.00) 0.8 (0.2–3.6) 0.6 (0.1–2.8)
Overlapping quadrants 413 27.1 19 23.5 0.93 (0.89–0.96) 1.1 (0.6–2.1) 1.1 (0.6–2.0)
Unknown 19 1.2 6 7.4 0.69 (0.47–0.92) – –
aHazard ratio adjusted for age (variable in continuous), period of diagnosis, method of discovery, grade, tumor size, surgery, radiotherapy,
tumor location, histologic type, and hormone therapy; * P < 0.05, ** P < 0.01, *** P < 0.001.
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adjuvant chemotherapy in case of axillary or IMC
lymph node metastases.4,14,15 It is impossible to
evaluate an effect of undertreatment linked to un-
derstaging if node positive patients do not receive
adjuvant treatment. One study did not observe in-
creased breast cancer mortality but reported a sig-
niﬁcant increased risk of distant metastases in
patients with inner quadrant tumors who did not
receive chemotherapy.13 Longer follow-up will
probably show an increased mortality risk among
these patients.
Another explanation for the discrepancies between
the studies is that most previous studies included pa-
tients with positive axillary lymph nodes.9–12,24,25,27,28
As these patients were already candidates for adjuvant
therapy, the potential impact of undetected IMC
metastases on survival was low.Among the few studies
providing powerful subgroup analyses for lymph node
negative patients,9,12,25,29 the majority reported a
stronger effect of tumor location on breast cancer
mortality among lymph node negative patients.9,25,29
Like our study, the recent study of Colleoni and col-
leagues reported that the effect of tumor location was
greater for larger than for smaller tumours.9
As discussed above for the study of Veronesi and
colleagues, the discrepancies between previous studies
could also be explained by the dilution of the eﬀect of
the lower-inner quadrant, by regrouping this quad-
rant with other quadrants.4 Unfortunately, most
studies reporting an association between breast
location and survival did not distinguish between the
two inner quadrants or the two lower quadrants,
making it impossible to draw any conclusion for just
the lower-inner quadrant. When we regrouped pa-
tients with tumors of the inner quadrants and com-
pared them to patients with tumors of all other
quadrants, as performed in previous studies,9,10,12
we found a similar mortality risk (HR: 1.3, 95%CI:
0.8–2.2, P = 0.241). Also, when we regrouped pa-
tients with tumors of the lower quadrants and com-
pared them to patients with tumors of all other
quadrants, as performed in one other study,24 again
we observed very comparable results (HR: 1.7,
95%CI: 1.0–2.8, P = 0.058).
With the generalization of sentinel lymph node
biopsy for early breast cancer,21,22,30 studies on the
importance and consequences of IMC involvement
among patients without axillary lymph node metas-
tases become increasingly important. Systematic
investigation of sentinel nodes of the IMC is feasible
with an experienced team of professionals, even if
difﬁculties exist in distinguishing between the radio-
activity of the primary tumor located in the internal
site of the breast and the radioactivity of the involved
sentinel nodes in the IMC.
In conclusion, tumor location in the lower-inner
quadrant is an independent and important prognostic
factor for patients with node negative breast cancer.
If further research demonstrates that this over-mor-
tality is indeed due to a higher frequency of unde-
tected IMC metastases, patients with stage I breast
cancer of the lower-inner quadrant should become
candidates for systematic evaluation of the IMC.
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